Strategy for eliciting antigen-specific CD8+ T cell-mediated immune response against a cryptic CTL epitope of merkel cell polyomavirus large T antigen

Cell & Bioscience

Chien-Fu Hung³  T-C Wu²  Liangmei He¹  Shiwen Peng¹  Raphael P Viscidi⁴  Connie Wang¹  Bianca P Gomez¹ 

[1] Departments of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD, USA;Oncology, Johns Hopkins Medical Institutions, Baltimore, MD, USA;Departments of Pathology and Oncology, The Johns Hopkins University School of Medicine, CRB II Room 307, 1550 Orleans Street, Baltimore, MD, 21231, USA;Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA

关键词: Large T antigen;    Cryptic CTL Epitope;    Merkel cell polyomavirus;    Gene therapy;    DNA vaccine;   

Others  :  793126
DOI  :  10.1186/2045-3701-2-36

 received in 2012-05-15, accepted in 2012-09-19,  发布年份 2012

【 摘 要 】

Background

Merkel cell carcinoma (MCC) is a relatively new addition to the expanding category of oncovirus-induced cancers. Although still comparably rare, the number of cases has risen dramatically in recent years. Further complicating this trend is that MCC is an extremely aggressive neoplasm with poor patient prognosis and limited treatment options for advanced disease. The causative agent of MCC has been identified as the merkel cell polyomavirus (MCPyV). The MCPyV-encoded large T (LT) antigen is an oncoprotein that is theorized to be essential for virus-mediated tumorigenesis and is therefore, an excellent MCC antigen for the generation of antitumor immune responses. As a foreign antigen, the LT oncoprotein avoids the obstacle of immune tolerance, which normally impedes the development of antitumor immunity. Ergo, it is an excellent target for anti-MCC immunotherapy. Since tumor-specific CD8+ T cells lead to better prognosis for MCC and numerous other cancers, we have generated a DNA vaccine that is capable of eliciting LT-specific CD8+ T cells. The DNA vaccine (pcDNA3-CRT/LT) encodes the LT antigen linked to a damage-associated molecular pattern, calreticulin (CRT), as it has been demonstrated that the linkage of CRT to antigens promotes the induction of antigen-specific CD8+ T cells.

Results

The present study shows that DNA vaccine-induced generation of LT-specific CD8+ T cells is augmented by linking CRT to the LT antigen. This is relevant since the therapeutic effects of the pcDNA3-CRT/LT DNA vaccine is mediated by LT-specific CD8+ T cells. Mice vaccinated with the DNA vaccine produced demonstrably more LT-specific CD8+ T cells. The DNA vaccine was also able to confer LT-specific CD8+ T cell-mediated protective and therapeutic effects to prolong the survival of mice with LT-expressing tumors. In the interest of determining the LT epitope which most MCC-specific CD8+ T cells recognize, we identified the amino acid sequence of the immunodominant LT epitope as aa19-27 (IAPNCYGNI) and found that it is H-2k^b-restricted.

Conclusion

The results of this study can facilitate the development of other modes of MCC treatment such as peptide-based vaccines and adoptive transfer of LT-specific CD8+ T cells. Likewise, the MCC DNA vaccine has great potential for clinical translation as the immunologic specificity is high and the treatment strategy can be exported to address other virus-induced tumors.

【 授权许可】

   
2012 Gomez et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE: Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 2010, 37(1):20-27. Epub 2009/07/30.
• [2]Hodgson NC: Merkel cell carcinoma: changing incidence trends. J Surg Oncol 2005, 89(1):1-4. Epub 2004/12/22.
• [3]Herbst A, Haynes HA, Nghiem P: The standard of care for Merkel cell carcinoma should include adjuvant radiation and lymph node surgery. J Am Acad Dermatol 2002, 46(4):640-642. Epub 2002/03/22.
• [4]Agelli M, Clegg LX, Becker JC, Rollison DE: The etiology and epidemiology of merkel cell carcinoma. Curr Probl Canc 2010, 34(1):14-37. Epub 2010/04/08.
• [5]Heath M, Jaimes N, Lemos B, Mostaghimi A, Wang LC, Penas PF, et al.: Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features. J Am Acad Dermatol 2008, 58(3):375-381. Epub 2008/02/19.
• [6]Becker JC, Houben R, Ugurel S, Trefzer U, Pfohler C, Schrama D: MC polyomavirus is frequently present in Merkel cell carcinoma of European patients. J Invest Dermatol 2009, 129(1):248-250. Epub 2008/07/18.
• [7]Feng H, Shuda M, Chang Y, Moore PS: Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008, 319(5866):1096-1100. Epub 2008/01/19.
• [8]Shuda M, Feng H, Kwun HJ, Rosen ST, Gjoerup O, Moore PS, et al.: T antigen mutations are a human tumor-specific signature for Merkel cell polyomavirus. Proc Natl Acad Sci USA 2008, 105(42):16272-16277. Epub 2008/09/25.
• [9]Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, et al.: Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer 2009, 125(6):1250-1256. Epub 2009/06/06.
• [10]Foulongne V, Kluger N, Dereure O, Mercier G, Moles JP, Guillot B, et al.: Merkel cell polyomavirus in cutaneous swabs. Emerg Infect Dis 2010, 16(4):685-687. Epub 2010/03/31.
• [11]Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, Angermeyer S, et al.: An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer 2012, 130(4):847-856. Epub 2011/03/18.
• [12]Houben R, Schrama D, Alb M, Pfohler C, Trefzer U, Ugurel S, et al.: Comparable expression and phosphorylation of the retinoblastoma protein in Merkel cell polyoma virus-positive and negative Merkel cell carcinoma. Int J Cancer 2010, 126(3):796-798. Epub 2009/07/29.
• [13]Zeng Q, Gomez BP, Viscidi RP, Peng S, He L, Ma B, et al.: Development of a DNA vaccine targeting Merkel cell polyomavirus. Vaccine 2012, 30(7):1322-1329. Epub 2012/01/03.
• [14]Erdag G, Schaefer JT, Smolkin ME, Deacon DH, Shea SM, Dengel LT, et al.: Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012, 72(5):1070-1080. Epub 2012/01/24.
• [15]Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al.: Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol Offic J Am Soc Clin Oncol 2011, 29(15):1949-1955. Epub 2011/04/13.
• [16]Sihto H, Bohling T, Kavola H, Koljonen V, Salmi M, Jalkanen S, et al.: Tumor Infiltrating Immune Cells And Outcome of Merkel Cell Carcinoma: A Population-based Study. Clin Canc Res Offic J Am Assoc Canc Res 2012. Epub 2012/04/03.
• [17]Paulson KG, Iyer JG, Tegeder AR, Thibodeau R, Schelter J, Koba S, et al.: Transcriptome-wide studies of merkel cell carcinoma and validation of intratumoral CD8+ lymphocyte invasion as an independent predictor of survival. J Clin Oncol Offic J Am Soc Clin Oncol 2011, 29(12):1539-1546. Epub 2011/03/23.
• [18]Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, et al.: Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005, 123(2):321-334. Epub 2005/10/22.
• [19]Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T, et al.: A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012, 31(5):1062-1079. Epub 2012/01/19.
• [20]Cheng WF, Hung CF, Chen CA, Lee CN, Su YN, Chai CY, et al.: Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine 2005, 23(29):3864-3874. Epub 2005/05/17.
• [21]Peng S, Ji H, Trimble C, He L, Tsai YC, Yeatermeyer J, et al.: Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6. J Virol 2004, 78(16):8468-8476. Epub 2004/07/29.
• [22]Kim D, Gambhira R, Karanam B, Monie A, Hung CF, Roden R, et al.: Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008, 26(3):351-360. Epub 2007/12/22.
• [23]Zemmour J, Little AM, Schendel DJ, Parham P: The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J Immunol 1992, 148(6):1941-1948. Epub 1992/03/15.
• [24]Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, et al.: Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 2001, 108(5):669-678. Epub 2001/09/07.
• [25]Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al.: Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000, 60(4):1035-1042. Epub 2000/03/08.
• [26]Hung CF, Cheng WF, He L, Ling M, Juang J, Lin CT, et al.: Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes. Cancer Res 2003, 63(10):2393-2398. Epub 2003/05/17.
• [27]Hung CF, Cheng WF, Hsu KF, Chai CY, He L, Ling M, et al.: Cancer immunotherapy using a DNA vaccine encoding the translocation domain of a bacterial toxin linked to a tumor antigen. Cancer Res 2001, 61(9):3698-3703. Epub 2001/04/28.
• [28]Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, et al.: Merkel cell polyomavirus-specific CD8 and CD4 T-cell responses identified in Merkel cell carcinomas and blood. Clin Canc Res Offic J Am Assoc Canc Res 2011, 17(21):6671-6680. Epub 2011/09/13.
• [29]Kubo H, Matsushita S, Fukushige T, Kanzaki T, Kanekura T: Spontaneous regression of recurrent and metastatic Merkel cell carcinoma. J Dermatol 2007, 34(11):773-777. Epub 2007/11/02.
• [30]Wooff JC, Trites JR, Walsh NM, Bullock MJ: Complete spontaneous regression of metastatic merkel cell carcinoma: a case report and review of the literature. Am J Dermatopathol 2010, 32(6):614-617. Epub 2010/06/04.